cisapride has been researched along with e 4031 in 21 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (4.76) | 18.2507 |
| 2000's | 15 (71.43) | 29.6817 |
| 2010's | 5 (23.81) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cavalli, A; De Ponti, F; Poluzzi, E; Recanatini, M | 1 |
| Keserü, GM | 1 |
| Nagashima, R; Nishikawa, T; Tobita, M | 1 |
| Bianucci, AM; Calderone, V; Coi, A; Massarelli, I; Testai, L | 1 |
| Jia, L; Sun, H | 1 |
| Caron, G; Ermondi, G; Visentin, S | 1 |
| Sen, S; Sinha, N | 1 |
| Fijorek, K; Glinka, A; Mendyk, A; Polak, S; Wiśniowska, B | 1 |
| Gong, Q; January, CT; Zhou, Z | 1 |
| Carl, A; Kenyon, JL; Sanders, KM | 1 |
| Brown, AM; Ficker, E; Obejero-Paz, CA; Zhao, S | 1 |
| Avery, MJ; DePasquale, MJ; Fossa, AA; Leishman, DJ; Raunig, DL | 1 |
| Avery, M; Fermini, B; Fossa, AA; Raunig, DL; Wang, E; Wisialowski, T; Wolfgang, E | 1 |
| Antzelevitch, C; Di Diego, JM; Fish, JM; Nesterenko, V | 1 |
| Abe, J; Hamada, Y; Harada, T; Hashimoto, K; Horii, I; Sawada, Y; Shiotani, M | 1 |
| Anderson, CL; Anson, BD; Delisle, BP; Eckhardt, LL; Gillman, BM; Holzem, KM; January, CT; Klemens, CA; Makielski, JC; Rajamani, S; Valdivia, CR | 1 |
| Cox, BF; Fischer, C; Gintant, GA; Limberis, JT; Long, MA; Martin, RL; Mikhail, A; Patel, A; Su, Z | 1 |
| Imai, YN; Oiki, S; Ryu, S | 1 |
| Hihara, T; Ito, M; Kohmura, N; Sawada, K; Taniguchi, T; Yamazaki, K; Yoshinaga, T | 1 |
| Fujii, M; Imaizumi, Y; Ohya, S; Yamamura, H | 1 |
| Ando, H; Asakura, K; Hayashi, S; Kanda, Y; Kasai, C; Miyamoto, N; Ojima, A; Osada, T; Sawada, K; Sekino, Y; Sugiyama, A; Taniguchi, T; Tashibu, H; Uda, T; Yamamoto, W; Yamazaki, D; Yoshinaga, T | 1 |
21 other study(ies) available for cisapride and e 4031
| Article | Year |
|---|---|
Toward a pharmacophore for drugs inducing the long QT syndrome: insights from a CoMFA study of HERG K(+) channel blockers.
Topics: Anti-Arrhythmia Agents; Cation Transport Proteins; Cluster Analysis; Databases, Factual; Ether-A-Go-Go Potassium Channels; Long QT Syndrome; Models, Molecular; Molecular Conformation; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Voltage-Gated; Quantitative Structure-Activity Relationship | 2002 |
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.
Topics: Cation Transport Proteins; Databases, Factual; Discriminant Analysis; Ether-A-Go-Go Potassium Channels; Holography; Linear Models; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Voltage-Gated; Quantitative Structure-Activity Relationship | 2003 |
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.
Topics: Animals; CHO Cells; Cricetinae; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Potassium Channel Blockers; Potassium Channels, Voltage-Gated | 2005 |
Identification of "toxicophoric" features for predicting drug-induced QT interval prolongation.
Topics: Amino Acid Sequence; Heart; Humans; Models, Molecular; Molecular Sequence Data; Molecular Structure; Protein Subunits; Sequence Alignment; Structure-Activity Relationship; Trans-Activators; Transcriptional Regulator ERG | 2008 |
Support vector machines classification of hERG liabilities based on atom types.
Topics: Animals; Arrhythmias, Cardiac; CHO Cells; Computer Simulation; Cricetinae; Cricetulus; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Models, Chemical; Patch-Clamp Techniques; Potassium Channel Blockers; Potassium Channels, Voltage-Gated; Predictive Value of Tests; ROC Curve | 2008 |
GRIND-based 3D-QSAR and CoMFA to investigate topics dominated by hydrophobic interactions: the case of hERG K+ channel blockers.
Topics: Ether-A-Go-Go Potassium Channels; Humans; Hydrophobic and Hydrophilic Interactions; Models, Molecular; Potassium Channel Blockers; Quantitative Structure-Activity Relationship | 2009 |
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.
Topics: Computer Simulation; Ether-A-Go-Go Potassium Channels; Humans; Molecular Structure; Organic Chemicals; Quantitative Structure-Activity Relationship | 2011 |
Predictive model for L-type channel inhibition: multichannel block in QT prolongation risk assessment.
Topics: Artificial Intelligence; Calcium Channel Blockers; Calcium Channels, L-Type; Cell Line; Computational Biology; Computer Simulation; Drugs, Investigational; Ether-A-Go-Go Potassium Channels; Expert Systems; Heart Rate; Humans; Models, Biological; Myocytes, Cardiac; NAV1.5 Voltage-Gated Sodium Channel; Potassium Channel Blockers; Quantitative Structure-Activity Relationship; Risk Assessment; Shaker Superfamily of Potassium Channels; Torsades de Pointes; Voltage-Gated Sodium Channel Blockers | 2012 |
Correction of defective protein trafficking of a mutant HERG potassium channel in human long QT syndrome. Pharmacological and temperature effects.
Topics: Anti-Arrhythmia Agents; Astemizole; Biological Transport; Cation Transport Proteins; Cell Compartmentation; Cisapride; DNA-Binding Proteins; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Glycerol; Humans; Long QT Syndrome; Mutation; Patch-Clamp Techniques; Piperidines; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Voltage-Gated; Protein Folding; Pyridines; Recombinant Proteins; Temperature; Trans-Activators; Transcriptional Regulator ERG | 1999 |
Alosetron and the rapid component of delayed rectifying potassium current in cardiac cells.
Topics: Animals; Carbolines; Cisapride; Delayed Rectifier Potassium Channels; Guinea Pigs; Heart; In Vitro Techniques; Membrane Potentials; Myocardium; Patch-Clamp Techniques; Piperidines; Potassium Channels; Potassium Channels, Voltage-Gated; Pyridines; Receptors, Serotonin; Receptors, Serotonin, 5-HT3; Serotonin Antagonists | 2001 |
The binding site for channel blockers that rescue misprocessed human long QT syndrome type 2 ether-a-gogo-related gene (HERG) mutations.
Topics: Anti-Arrhythmia Agents; Astemizole; Benzimidazoles; Binding Sites; Blotting, Western; Cation Transport Proteins; Cell Line; Cell Membrane; Cisapride; DNA-Binding Proteins; Dose-Response Relationship, Drug; Electrophysiology; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Gastrointestinal Agents; Histamine H1 Antagonists; Humans; Inhibitory Concentration 50; Ions; Long QT Syndrome; Models, Chemical; Mutagenesis, Site-Directed; Mutation; Patch-Clamp Techniques; Piperidines; Potassium Channels; Potassium Channels, Voltage-Gated; Protein Folding; Pyridines; Quaternary Ammonium Compounds; Quinidine; Structure-Activity Relationship; Trans-Activators; Transcriptional Regulator ERG | 2002 |
The relationship of clinical QT prolongation to outcome in the conscious dog using a beat-to-beat QT-RR interval assessment.
Topics: Animals; Anti-Arrhythmia Agents; Butylamines; Cisapride; Disease Models, Animal; Dogs; Female; Heart Rate; Long QT Syndrome; Male; Piperidines; Pyridines; Terfenadine; Verapamil | 2002 |
Differential effect of HERG blocking agents on cardiac electrical alternans in the guinea pig.
Topics: Animals; Antipsychotic Agents; Bepridil; Blood Pressure; Calcium Channel Blockers; Calcium Channels, L-Type; Cisapride; Delayed Rectifier Potassium Channels; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Gastrointestinal Agents; Guinea Pigs; Heart Rate; Histamine H1 Antagonists; Humans; In Vitro Techniques; Male; Myocytes, Cardiac; Patch-Clamp Techniques; Piperidines; Potassium Channels, Voltage-Gated; Pyridines; Risperidone; Terfenadine; Verapamil | 2004 |
Epicardial activation of left ventricular wall prolongs QT interval and transmural dispersion of repolarization: implications for biventricular pacing.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Cardiac Pacing, Artificial; Cisapride; Computer Simulation; Delayed Rectifier Potassium Channels; Dogs; Electrocardiography; Endocardium; Heart Ventricles; Membrane Potentials; Models, Cardiovascular; Pericardium; Piperidines; Potassium Channels; Potassium Channels, Voltage-Gated; Pyridines; Torsades de Pointes | 2004 |
Practical application of guinea pig telemetry system for QT evaluation.
Topics: Animals; Anti-Arrhythmia Agents; Antipsychotic Agents; Bepridil; Cisapride; Disease Models, Animal; Electrocardiography; Guinea Pigs; Haloperidol; Heart; Humans; Injections, Intravenous; Long QT Syndrome; Male; Nifedipine; Pimozide; Piperidines; Pyridines; Quinidine; Reproducibility of Results; Telemetry; Terfenadine; Thioridazine | 2005 |
Drug-induced long QT syndrome: hERG K+ channel block and disruption of protein trafficking by fluoxetine and norfluoxetine.
Topics: Adult; Antidepressive Agents, Second-Generation; Blotting, Western; Cell Line; Cell Membrane; Cisapride; Dose-Response Relationship, Drug; Drug Overdose; Ether-A-Go-Go Potassium Channels; Female; Fluoxetine; Humans; Long QT Syndrome; Membrane Potentials; Muscle Proteins; Mutation; NAV1.5 Voltage-Gated Sodium Channel; Patch-Clamp Techniques; Piperidines; Protein Transport; Pyridines; Sodium Channels; Time Factors; Transfection | 2006 |
Hydroxypropyl beta-cyclodextrins: a misleading vehicle for the in vitro hERG current assay.
Topics: 2-Hydroxypropyl-beta-cyclodextrin; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; beta-Cyclodextrins; Biological Assay; Cisapride; Dose-Response Relationship, Drug; Electrophysiology; Ether-A-Go-Go Potassium Channels; Excipients; Gastrointestinal Agents; Histamine H1 Antagonists; Humans; Inhibitory Concentration 50; Myocytes, Cardiac; Piperidines; Potassium Channel Blockers; Pyridines; Solubility; Terfenadine; Time Factors | 2007 |
Docking model of drug binding to the human ether-à-go-go potassium channel guided by tandem dimer mutant patch-clamp data: a synergic approach.
Topics: Amino Acid Sequence; Binding Sites; Cell Line; Cisapride; Dimerization; Ether-A-Go-Go Potassium Channels; Humans; Models, Molecular; Molecular Sequence Data; Mutation; Patch-Clamp Techniques; Piperidines; Pyridines; Sequence Homology, Amino Acid; Terfenadine | 2009 |
A novel method of selecting human embryonic stem cell-derived cardiomyocyte clusters for assessment of potential to influence QT interval.
Topics: Cisapride; Drug Evaluation, Preclinical; Embryonic Stem Cells; Ether-A-Go-Go Potassium Channels; Humans; Myocytes, Cardiac; Piperidines; Potassium Channel Blockers; Pyridines | 2012 |
Development of recombinant cell line co-expressing mutated Nav1.5, Kir2.1, and hERG for the safety assay of drug candidates.
Topics: Action Potentials; Biological Assay; Cell Line; Cisapride; Drug Evaluation, Preclinical; Ether-A-Go-Go Potassium Channels; HEK293 Cells; High-Throughput Screening Assays; Humans; NAV1.5 Voltage-Gated Sodium Channel; Patch-Clamp Techniques; Piperidines; Potassium Channel Blockers; Potassium Channels, Inwardly Rectifying; Pyridines; Pyrimidinones; Sodium Channels; Terfenadine; Transfection; Verapamil | 2012 |
Electrophysiological Characteristics of Human iPSC-Derived Cardiomyocytes for the Assessment of Drug-Induced Proarrhythmic Potential.
Topics: Cells, Cultured; Chromans; Cisapride; Electrophysiological Phenomena; Heart Rate; Humans; Induced Pluripotent Stem Cells; Linear Models; Models, Cardiovascular; Myocytes, Cardiac; Piperidines; Pyridines; Sulfonamides; Torsades de Pointes | 2016 |